InnoSign: Eric Lindquist, Paul van de Wiel

Eric Lindquist has been appointed as CEO of InnoSign, a Dutch company offering an mRNA-based pathway activity profiling test called OncoSignal. He will replace cofounder Paul van de Wiel as CEO, who will remain chief operating officer and a board observer. Lindquist previously served as chief business and chief commercial officer at biotechnology firm Celcuity. Before that, he was global VP of the oncology and transplant business and commercial development at Natera. He also worked in business development, sales, and marketing at Cynvenio Biosystems, Asuragen, HTG Molecular Diagnostics, Roche, Apocell, J&J Life Sciences, and Abbott Laboratories. He holds a BS in genetics and cell biology from the University of Minnesota and an MBA from Capella University.